OOIR: Observatory of International Research

Papers

(The H4-Index of JAMA Dermatology is 45. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040	289
Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis	248
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis	243
Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis	190
Psoriasis Prevalence in Adults in the United States	176
Patient Perspectives on the Use of Artificial Intelligence for Skin Cancer Screening	139
Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis	124
Evaluation of Chilblains as a Manifestation of the COVID-19 Pandemic	115
Lack of Transparency and Potential Bias in Artificial Intelligence Data Sets and Algorithms	110
Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine	107
Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis	103
Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis	96
Prevalence of Hidradenitis Suppurativa	91
Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa	86
Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne	79
Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis	78
Clinical, Laboratory, and Interferon-Alpha Response Characteristics of Patients With Chilblain-like Lesions During the COVID-19 Pandemic	78
Systemic Immunomodulatory Treatments for Atopic Dermatitis	76
Petechial Skin Rash Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection	74
Checklist for Evaluation of Image-Based Artificial Intelligence Reports in Dermatology	74
UBA1 Variations in Neutrophilic Dermatosis Skin Lesions of Patients With VEXAS Syndrome	70
Digitate Papulosquamous Eruption Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection	68
Association Between Medication Use and Bullous Pemphigoid	68
Evaluation of Sex-Specific Incidence of Melanoma	64
Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Therapy	62

Incidence of Cutaneous Reactions After Messenger RNA COVID-19 Vaccines	62
UV Exposure and the Risk of Cutaneous Melanoma in Skin of Color	62
Assessment of Acute Acral Lesions in a Case Series of Children and Adolescents During the COVID-19 Pandemic	61
Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders	60
Association of Wildfire Air Pollution and Health Care Use for Atopic Dermatitis and Itch	59
Secukinumab Therapy for Netherton Syndrome	58
Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis	58
Enanthem in Patients With COVID-19 and Skin Rash	57
Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride	57
Association Between Early Severe Cardiovascular Events and the Initiation of Treatment With the Anti–Interleukin 12/23p40 Antibody Ustekinumab	56
Dermatologist Perceptions of Teledermatology Implementation and Future Use After COVID-19	56
Mucocutaneous Manifestations of Multisystem Inflammatory Syndrome in Children During the COVID-19 Pandemic	55
Prognostic Gene Expression Profiling in Cutaneous Melanoma	55
Sirolimus (Rapamycin) for Slow-Flow Malformations in Children	52
Association Between Atopic Eczema and Cancer in England and Denmark	51
Insurance Acceptance, Appointment Wait Time, and Dermatologist Access Across Practice Types in the US	49
Association Between Psoriasis and Nonalcoholic Fatty Liver Disease Among Outpatient US Adults	49
Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases	48
Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis	45
Association Between Adult Acne and Dietary Behaviors	45